1. The reason for the rebound of medicine: oversold + collection does not fundamentally change
last week's pharmaceutical sector rebounded sharply because it was stimulated by news. Recently, the National Health Insurance Administration has made it clear that innovative medical devices will not be included in the centralized procurement for the time being!
However, medical insurance collection is a major trend. Because of the trend of aging in China and the inadequate social security costs, it cannot afford high medical expenses. With the three years of epidemic and the economy has declined, the government's money bag has become even more deflated. Medical collection is the future trend!
so the rebound of the pharmaceutical sector is not optimistic, it is just an oversold + emotional stimulation, not a fundamental reversal. The subsequent policy will be restored to the high collection of medical and medical equipment.
2. So is it always bad for innovative drugs?
won't. The collection of medical policies only reduces the high price of medicine. The market demand exists objectively and will become larger and larger. After all, there will be more and more difficult and complicated diseases.
On the other hand, only technologically innovating companies can obtain the collection of government and encourage companies to continue to maintain innovation. Like Hengrui Medicine , 10 years ago, I made a lot of money with a drug. Now its technology has been surpassed by other companies and its price is even cheaper, so naturally its share has been lost. Therefore, the decline of Hengrui is the fundamental logic. On the contrary, it is beneficial to innovative companies.
Therefore, this wave of rebound in the pharmaceutical industry is not a fundamental rebound, but an oversold rebound. It will inevitably be a differentiation in the later stage. It is a company with technological innovation, and companies with performance growth can continue to rise.
Only pharmaceutical companies with upward trends can have the last laugh! Let's continue watching next.
3. How to choose to avoid pitfalls behind the excitement? In terms of
funds, Wind shows that the pharmaceutical and biological industry received a net inflow of 6.483 billion yuan in main funds, ranking first in the first-level industries in Shenwan. Among them, Hengrui, WuXiang and Changchun Gao received net inflows of 951 million yuan, 756 million yuan and 492 million yuan respectively. Appearing in the after-hours dragon and tiger list on the Shanghai and Shenzhen Stock Exchanges, such as Dirui , Mike Sheng, Kaili, Wuzhou, and New Industry!
will not be expanded here! The rebound of the downward trend: Facing the above layers of trapped and unblocking pressure
